Ask AI
ADCs in Solid Tumors
What Oncology Pharmacists Need to Know About ADCs in Solid Tumor Management

Released: June 27, 2025

Expiration: December 26, 2025

Activity

Progress
1
Course Completed

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:

  • An overview of ADC structure and mechanism of action
  • A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types
  • An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies

Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy.